All In Biotech

Drug Trial Radar · NCT06109948

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

A Phase 1a/1b, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABX1100 in Normal Healthy Volunteers and Late-onset Pompe Disease Patients

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Oct 19, 2023

Primary completion

Feb 13, 2026

Study completion Feb 13, 2026

Sponsor

Lead sponsor
Aro BiotherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study ABX1100-1001 is a first-in-human (FIH), phase 1 study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) and multiple doses (MD) of ABX1100 administered intravenously to healthy participants and patients with LOPD. * Part A features a SAD study with a double-blind, placebo-controlled, randomized design in NHVs involving 3 cohorts (A1-A3). This Part also includes a single dose, open-labeled cohort (A4) in NHVs which will commence after cohorts A1-3. * Part B is a MD, double-blind, placebo-controlled, randomized design in NHVs. The MD Part B will commence after completion of Cohorts A1, A2 and A3 in the SAD Part A and SRC review of these 3 cohorts. * Part C opened for enrollment after the Safety Review Committee (SRC) review of safety, PK and PD data from both Part A and Part B. Part C is a MD, open-label design in patients with Late-Onset Pompe Disease.

Conditions

  • Healthy
  • Late Onset Pompe Disease

Interventions

  • ABX1100 injection for IV infusionDrug

    Centyrin protein-siRNA conjugate

  • Placebo injection for IV infusionDrug

    placebo saline injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with treatment-emergent adverse events (TEAEs)Time frame: up to 20 weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • UCI

    Orange, California

  • Washington University School of Medicine

    St Louis, Missouri

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc

    Fairfax, Virginia

  • MAGIC clinic

    Calgary, Alberta, Canada

  • McMaster University

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.